Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LRP6 antibody
- Development stage
- Preclinical
- Lead developer
- WntGen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal, Intraperitoneal, Subcutaneous, Intravenous, Intramuscular, Inhalation, Intranasal, Topical, Oral, Transdermal, Rectal, Buccal, Intradermal, Intrathecal, Intratumoral, Parenteral, Implant
01
Overview
The LRP6 antibody is a therapeutic monoclonal antibody being developed by WntGen LLC, a biotechnology company incubated by Panorama Research, for the treatment of fibrotic diseases. LRP6 (Low-density lipoprotein receptor-related protein 6) is a vital co-receptor in the canonical Wnt/beta-catenin signaling pathway. Dysregulation and overactivation of this pathway are strongly associated with the pathogenesis of fibrosis in various organs, including the lungs, kidneys, and liver, by promoting the activation of fibroblasts into collagen-secreting myofibroblasts. By binding to and inhibiting LRP6, this antibody blocks the interaction between Wnt ligands and their receptor complex, thereby attenuating pro-fibrotic gene expression and disease progression. The program is currently in the preclinical stage of development.
- Other names
- LRP6 antibodyLRP-6 antibodyLRP 6 antibodyanti-LRP6 antibodyanti-LRP-6 antibodyanti-LRP 6 antibodyanti-LRP6 monoclonal antibodyanti-LRP-6 monoclonal antibodyanti-LRP 6 monoclonal antibody
02
Targets
LRP6 (Low-density lipoprotein receptor-related protein 6)
Beyond the preview
Go deeper on LRP6 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LRP6 antibody.